Revolutionary Brain Tumour Therapy Cuts Recurrence by 90% in Landmark Trial

A groundbreaking radiation therapy for brain tumours has shown dramatic results in a major clinical trial. The new approach, called tile-based radiation therapy (TBRT), slashed recurrence rates and more than doubled survival times compared to the current standard treatment. Researchers at The University of Texas MD Anderson Cancer Center led the study, which could change how brain metastases are managed after surgery. The trial, named ROADS, tested TBRT against the standard postoperative stereotactic radiation therapy (SRT). Patients treated with TBRT experienced a recurrence rate of just 1.3% at the surgical site after one year. In contrast, those receiving SRT saw a 15.4% recurrence rate over the same period.

TBRT works by implanting thin, flexible tiles lined with microscopic cesium-131 seeds into the surgical cavity during tumour removal. These seeds, embedded in a dissolvable collagen matrix, deliver continuous low-dose radiation directly to the area where cancer cells might remain. Unlike SRT, which requires multiple sessions over weeks, TBRT completes treatment in a single day. The results were striking. Median overall survival for TBRT patients reached 42.5 months—over twice as long as the 17.6 months observed with SRT. Scientists attribute this success to the therapy’s precision timing, which targets residual cancer cells before they can grow or resist treatment. Importantly, TBRT did not increase the risk of radiation necrosis, a severe side effect where brain tissue is permanently damaged. Beyond its effectiveness, TBRT simplifies recovery. Patients spent just one day in treatment instead of the 32 days typically needed for SRT. This allows them to start additional cancer therapies sooner, improving overall care efficiency.

The trial’s findings highlight TBRT as a major advance in brain metastasis treatment. With lower recurrence rates, extended survival, and a streamlined recovery process, the therapy offers clear benefits over existing methods. Further adoption could depend on regulatory reviews and broader clinical implementation.